Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million
31/08/2026 03:01
BRIEF-Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million Aug 31 (Reuters) - Cynata Therapeutics Ltd CYP.AX:
FY2026 LOSS FROM ORDINARY ACTIVITIES AFTER TAX A$9.1 MILLION
FY2026 REVENUE FROM ORDINARY ACTIVITIES DOWN 15.23% TO A$1.8 MILLION
NO DIVIDENDS DECLARED FOR FY2026
Further company coverage: CYP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cynata Therapeutics
See all newsBrief: Cynata Therapeutics Says Firm Commitments Received To Raise Further A$550,000 Via Placement
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million